United States - English - NLM (National Library of Medicine)

msn laboratories private limited - toremifene citrate (unii: 2498y783qt) (toremifene - unii:7nfe54o27t) - toremifene citrate tablets are estrogen agonist/antagonist indicated for the treatment of metastatic breast cancer in postmenopausal women with estrogen-receptor positive or unknown tumors. toremifene citrate is contraindicated in patients with known hypersensitivity to the drug. toremifene should not be prescribed to patients with congenital/acquired qt prolongation (long qt syndrome), uncorrected hypokalemia, or uncorrected hypomagnesemia. pregnancy category d [see warnings and precautions (5.6).] based on its mechanism of action in humans and findings of increased pregnancy loss and fetal malformation in animal studies, toremifene citrate can cause fetal harm when administered to a pregnant woman. toremifene caused embryo-fetal toxicities at maternal doses that were lower than the 60 mg daily recommended human dose on a mg/m2 basis. there are no adequate and well-controlled studies in pregnant women using toremifene citrate. if this drug is used during pregnancy, or if the patient becomes pregnant whi

United States - English - NLM (National Library of Medicine)

novadoz pharmaceuticals llc - toremifene citrate (unii: 2498y783qt) (toremifene - unii:7nfe54o27t) - toremifene citrate tablets are estrogen agonist/antagonist indicated for the treatment of metastatic breast cancer in postmenopausal women with estrogen-receptor positive or unknown tumors. toremifene citrate is contraindicated in patients with known hypersensitivity to the drug. toremifene should not be prescribed to patients with congenital/acquired qt prolongation (long qt syndrome), uncorrected hypokalemia, or uncorrected hypomagnesemia. pregnancy category d [see warnings and precautions (5.6).] based on its mechanism of action in humans and findings of increased pregnancy loss and fetal malformation in animal studies, toremifene citrate can cause fetal harm when administered to a pregnant woman. toremifene caused embryo-fetal toxicities at maternal doses that were lower than the 60 mg daily recommended human dose on a mg/m2 basis. there are no adequate and well-controlled studies in pregnant women using toremifene citrate. if this drug is used during pregnancy, or if the patient becomes pregnant whi

United States - English - NLM (National Library of Medicine)

rising pharmaceuticals, inc. - toremifene citrate (unii: 2498y783qt) (toremifene - unii:7nfe54o27t) - toremifene citrate tablets are an estrogen agonist/antagonist indicated for the treatment of metastatic breast cancer in postmenopausal women with estrogen-receptor positive or unknown tumors. toremifene citrate tablets are contraindicated in patients with known hypersensitivity to the drug. toremifene should not be prescribed to patients with congenital/acquired qt prolongation (long qt syndrome), uncorrected hypokalemia, or uncorrected hypomagnesemia. pregnancy category d [see warnings and precautions (5.6)] based on its mechanism of action in humans and findings of increased pregnancy loss and fetal malformation in animal studies, toremifene citrate tablets can cause fetal harm when administered to a pregnant woman. toremifene caused embryo-fetal toxicities at maternal doses that were lower than the 60 mg daily recommended human dose on a mg/m2 basis. there are no adequate and well-controlled studies in pregnant women using toremifene citrate tablets. if this drug is used during pregnancy, or if the patie

United States - English - NLM (National Library of Medicine)

kyowa kirin, inc. - toremifene citrate (unii: 2498y783qt) (toremifene - unii:7nfe54o27t) - toremifene 60 mg - fareston® is an estrogen agonist/antagonist indicated for the treatment of metastatic breast cancer in postmenopausal women with estrogen-receptor positive or unknown tumors. fareston is contraindicated in patients with known hypersensitivity to the drug. toremifene should not be prescribed to patients with congenital/acquired qt prolongation (long qt syndrome), uncorrected hypokalemia, or uncorrected hypomagnesemia. pregnancy category d [see warnings and precautions (5.7).] based on its mechanism of action in humans and findings of increased pregnancy loss and fetal malformation in animal studies, fareston can cause fetal harm when administered to a pregnant woman. toremifene caused embryo-fetal toxicities at maternal doses that were lower than the 60 mg daily recommended human dose on a mg/m2 basis. there are no adequate and well-controlled studies in pregnant women using fareston. if this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be appris

Australia - English - Department of Health (Therapeutic Goods Administration)

orion pharma (aus) pty limited - toremifene citrate, quantity: 88.5 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; colloidal anhydrous silica; sodium starch glycollate; microcrystalline cellulose; magnesium stearate; povidone; maize starch - for the first line treatment of hormone-dependent metastatic breast cancer in postmenopausal women. it is not recommended for patients with oestrogen receptor negative tumours.

Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

sawai pharmaceutical co.,ltd. - toremifene citrate - white tablet, diameter: 7.5 mm, thickness: 3.2 mm

Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

sawai pharmaceutical co.,ltd. - toremifene citrate - white tablet, diameter: 9.0 mm, thickness: 3.5 mm

New Zealand - English - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - toremifene citrate 88.5mg equivalent to 60 mg toremifene - tablet - 60 mg - active: toremifene citrate 88.5mg equivalent to 60 mg toremifene excipient: colloidal silicon dioxide lactose monohydrate magnesium stearate maize starch microcrystalline cellulose povidone sodium starch glycolate

European Union - English - EMA (European Medicines Agency)

orion corporation - toremifene - breast neoplasms - endocrine therapy - first line hormone treatment of hormone-dependent metastatic breast cancer in postmenopausal patients.fareston is not recommended for patients with estrogen receptor negative tumours.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

orion pharma (uk - toremifene citrate - tablet - 60mg